We have six issued US Patents and fourteen follow on patent applications pending in the US and internationally. These claim advances in linker technology, the use of cleavable linkers in soluble circulating and solid supports, including hydrogels. Certain applications have claims directed towards specific therapeutic applications and compositions of matter.
May 16, 2017 9,649,385 Claims on biodegradable hydrogels
July 12, 2016 9,387,254 Claims on linkers
February 3, 2015 8,946,405 Claims on linkers on solid supports.
June 17, 2014 8,754,190 Claims on adapted linkers for non-amines.
April 22, 2014 8,703,907 Claims on dendrimers with releasable linkers.
March 25, 2014 8,680,315 Claims on linkers, soluble conjugates
August 2018 ProLynx and Daiichi Sanko announce the development of technology for the half-life extension of small molecules in the eye
April 2018 ProLynx announces allowance of additional U.S. patent for PLX038, a novel DNA damage response enhancer
April 2018 ProLynx extends lead in half-life extension platform technology-- Shows primary deuterium kinetic isotope effects prolong drug release and polymer biodegradation in a drug delivery system
Sept 2017 ProLynx announces SBIR grant award to develop novel technology for dual receptor agonists
June 2017 ProLynx announces collaboration with Daiichi Sankyo to evaluate drug delivery system in the eye
June 2017 ProLynx announces PLX039, a hydrogel-microsphere drug delivery system that supports once-monthly administration of a GLP-1 receptor agonist
May 2017ProLynx issued US patent for cleavable linker technology on hydrogels
June 2015 ProLynx announces active IND of a novel ultra-long acting PEG-SN-38 conjugate to treat solid tumors
February 2015 ProLynx issued key patent for using releasable linkers on insoluble carriers
November 2014 ProLynx awarded NSF Phase II grant for hydrogel platform research and development
August 2014 ProLynx enters funded evaluation agreement with GlaxoSmithKline Research & Development Limited (GSK)
June 2014 ProLynx granted US Patent 8,754,190 covering clinical candidate PEG-SN38
May 2014 ProLynx & RxGen publish data on ocular delivery platform at ARVO 2014 Annual Meeting
April 2014 US Patent 8,703,907 on controlled release from dendrimers
March 2014 Publication in JMedChem relating to PEG-SN-38 conjugates with ultra-long half life, low Cmax, and low glucuronide formation; Japanese partner advances toward Phase I trials.
March 2014 US Patent 8,680,315 on Beta-Eliminative Linkers
September 2012 Bayer Healthcare CoLaborator
April 2012 BioCentury
Copyright © Prolynx LLC. All rights reserved